Gladstone in the News
February 12, 2024
Fierce Biotech—A naturally occurring mutation in T cells that leads to lymphoma can be weaponized to make engineered T-cell therapies more effective against cancer, including melanoma, findings from a new study in mice suggest. The study’s co-leads, dermatologist Jaehyuk Choi and scientist Kole Roybal, have launched a new biotech company called Moonlight Bio to take their findings to the clinic.
Research (Publication)
Cancer
Genomic Immunology
Parker Institute for Cancer Immunotherapy
Roybal Lab
Genomics
Gladstone in the News
February 7, 2024
Nature—Cancer cells are the ultimate survivors, riddled with mutations that let them thrive when healthy cells would die. These same mutations can boost the ability of game-changing cell therapies to quash cancer, a study in mice shows. “Natural T-cell function isn’t good enough. We need to explore the extremes of T-cell function,” says Kole Roybal, co-author of the new paper.
Research (Publication)
Cancer
Genomic Immunology
Parker Institute for Cancer Immunotherapy
Roybal Lab
Genomics
Gladstone in the News
January 18, 2024
KCBS Radio—Diagnoses of autism spectrum disorder, or ASD, have been rising over the past decades, with one in 36 children identified with the condition in 2020 compared to one in 150 back in 2000, according to the US Centers for Disease Control and Prevention. Nevan Krogan, PhD, senior investigator at Gladstone Institutes and director of the Quantitative Biosciences Institute at UC San Francisco, shares new research on genetic changes that contribute to ASD.
Gladstone Experts
Research (Publication)
Neurological Disease
Krogan Lab
Gladstone in the News
January 16, 2024
BioTechniques—Researchers at Gladstone Institutes have mapped the human immune response using next-generation CRISPR technology known as base editing. Using this tool, the team was able to identify specific nucleotides within T cells that influence immune cells’ response to stimuli, creating maps of DNA sequences and protein sites that are involved in human immune responses. The discoveries this project has facilitated could improve existing immunotherapies and reveal new drug targets for autoimmune diseases and cancer.
Research (Publication)
Autoimmune Diseases
Cancer
Genomic Immunology
Doudna Lab
Marson Lab
CRISPR/Gene Editing
Genomics
Article
January 11, 2024
Scientists at Gladstone Institutes and UC San Francisco analyzed immune cells in people with and without long COVID, making significant discoveries that will help answer questions about what causes the condition and how to treat it
News Release
Research (Publication)
COVID-19
Virology
Roan Lab
Gladstone in the News
November 28, 2023
Genetic Engineering & Biotechnology News—Scientists at the Gladstone Institutes have published a paper in Cell Reports that describes a CRISPR-based technique for treating primary glioblastoma, a common and aggressive form of brain cancer. The paper, titled “Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis,” describes the technique, which the researchers have called “genome shredding.”
Research (Publication)
Cancer
Genomic Immunology
Doudna Lab
CRISPR/Gene Editing
